Modified gefitinib conjugated Fe₃O₄ NPs for improved delivery of chemo drugs following an image-guided mechanistic study of inner vs. outer tumor uptake for the treatment of non-small cell lung cancer.

ABSTRACT: Gefitinib (GEF) is an FDA-approved anti-cancer drug for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC). However, the efficacy of anticancer drugs is limited due to their non-specificity, lower accumulation at target sites, and systemic toxicity. Herein, we successfully synthesized a modified GEF (mGEF) drug and conjugated to Iron oxide nanoparticles (Fe₃O₄ NPs) for the treatment of NSCLC via magnetic resonance (MR) image-guided drug delivery. A traditional EDC coupling pathway uses mGEF to directly conjugate to Fe₃O₄ NPs to overcom the drug leakage issues. As a result, we found in vitro drug delivery on mGEF- Fe₃O₄ NPs exhibits excellent anticancer effects towards the PC9 cells

SUBMITTER: Thangudu S 

PROVIDER: S-EPMC10591449 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature